Clinical Trial Update: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Vudalimab or pembrolizumab with chemotherapy as first-line treatment for advanced nonsquamous non-small cell lung cancer has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vudalimab (XmAb20717)

Snippet

Sponsor: Xencor, Inc. | Conditions: Nonsquamous Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED